Because several independent studies have reported a higher risk of death for COVID-19 patients treated with Sulfasalazine, possibly associated with SLC7A11-independent inhibition of type I interferon production in vivo (Konig et al., 2022), we selected IKE to inhibit SLC7A11 in the following study. Here, SLC7A11 is linked to COVID-19.